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Attenuation of RNA polymerase II pausing
mitigates BRCA1-associated R-loop accumulation
and tumorigenesis
Xiaowen Zhang1,*, Huai-Chin Chiang1,*, Yao Wang1,*, Chi Zhang1, Sabrina Smith1, Xiayan Zhao1, Sreejith J. Nair1,
Joel Michalek2, Ismail Jatoi3, Meeghan Lautner3, Boyce Oliver3, Howard Wang3, Anna Petit4, Teresa Soler4,
Joan Brunet5, Francesca Mateo6, Miguel Angel Pujana6, Elizabeth Poggi7, Krysta Chaldekas7, Claudine Isaacs7,
Beth N. Peshkin7, Oscar Ochoa8, Frederic Chedin9, Constantine Theoharis10, Lu-Zhe Sun11, Tyler J. Curiel12,
Richard Elledge12, Victor X. Jin1, Yanfen Hu1 & Rong Li1
Most BRCA1-associated breast tumours are basal-like yet originate from luminal progenitors.
BRCA1 is best known for its functions in double-strand break repair and resolution of DNA
replication stress. However, it is unclear whether loss of these ubiquitously important
functions fully explains the cell lineage-specific tumorigenesis. In vitro studies implicate
BRCA1 in elimination of R-loops, DNA-RNA hybrid structures involved in transcription and
genetic instability. Here we show that R-loops accumulate preferentially in breast luminal
epithelial cells, not in basal epithelial or stromal cells, of BRCA1 mutation carriers.
Furthermore, R-loops are enriched at the 50 end of those genes with promoter-proximal RNA
polymerase II (Pol II) pausing. Genetic ablation of Cobra1, which encodes a Pol II-pausing and
BRCA1-binding protein, ameliorates R-loop accumulation and reduces tumorigenesis in
Brca1-knockout mouse mammary epithelium. Our studies show that Pol II pausing is
an important contributor to BRCA1-associated R-loop accumulation and breast cancer
development.
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G
erm-line BRCA1 mutations are associated with
significantly increased breast cancer incidence. Breast
epithelium consists of two layers: an inner layer of
luminal progenitors and mature luminal cells, and a basal
layer consisting of mammary stem cells and differentiated
myoepithelial cells1. Although most BRCA1-associated breast
tumours are basal-like, they originate from luminal progenitor
cells2–4. Unlike their counterparts from non-carriers, luminal
progenitor cells from BRCA1 mutation carriers exhibit
hormone-independent proliferation2 and attenuation of gene
expression associated with luminal differentiation4. More recent
studies indicate that the RANK–RANKL axis that drives
paracrine actions in luminal homeostasis is aberrantly activated
in BRCA1 mutation carriers5,6. At the molecular level, BRCA1 is
best known for its roles in supporting homologous recombination
(HR)-based double-strand break repair7–9 and suppressing DNA
replication stress10–15. However, it is not known whether loss of
these functions, which are ubiquitously important to all
proliferating cells, is sufficient to account for cell
lineage-specific tumorigenesis in breast epithelium of women
carrying BRCA1 mutations.
In addition to HR repair and DNA replication stress, BRCA1 is
implicated in transcriptional regulation7,16 and chromatin
reorganization17,18. Recent cell-line studies indicate that BRCA1
also has a role in elimination of R-loops, transcriptional
by-products that influence gene regulation and genomic
integrity19–21. We recently found HR repair-independent
functional antagonism between BRCA1 and cofactor of BRCA1
(COBRA1)22 during mouse mammary gland development.
COBRA1, also known as NELFB, is a BRCA1-binding
protein and an integral subunit of the RNA polymerase II
(Pol II)-pausing, negative elongation factor (NELF)17,23,24.
Consistent with a functional role of BRCA1 in transcription,
genome-wide studies found preferential association of BRCA1
with transcription start sites (TSS) in the human genome25–27.
However, whether a role of BRCA1 in transcription directly
contributes to BRCA1-associated tumorigenesis remains unclear.
Here we survey genome-wide R-loop dynamics in different
breast cell types from BRCA1 mutation carriers and non-carriers.
We found that BRCA1 mutation-associated R-loops preferentially
accumulate in luminal epithelial cells and at genomic loci with
paused Pol II. Using mouse genetic models, we further show
that attenuation of Pol II pausing reduces incidence of
Brca1-associated mouse mammary tumour incidence in a DNA
repair-independent manner. Our work thus uncovers a previously
unappreciated functional antagonism between BRCA1 and Pol II
pausing in breast tumorigenesis.
Results
R-loops in breast tissue of BRCA1 mutation carriers.
To ascertain clinical relevance of transcription-related BRCA1
functions, we first used immunofluorescence (IF) staining to
compare R-loop intensity in formalin-fixed paraffin-embedded
(FFPE), cancer-free breast tissue from BRCA1 mutation-carrying
women versus non-carriers. We found that R-loop intensity in
BRCA1 mutation carriers (B1, n¼ 55) was significantly higher
than that in non-carriers (NC, n¼ 36, Po0.001 by two-tailed
t-test, Fig. 1a,b). Pretreatment of the FFPE samples with RNase H,
which degrades RNA in R-loops, significantly reduced the IF
staining in BRCA1 mutation carriers (Fig. 1a), thus corroborating
specificity of the IF signals. A cohort of BRCA2 mutation carriers
exhibited similar increase in R-loop intensity as compared
to non-carriers, but the difference did not reach statistical
significance (Supplementary Fig. 1). Notably, the vast majority of
luminal epithelial cells in a typical BRCA1 mutation
carrier sample exhibited elevated R-loop staining, whereas basal
epithelial and stromal cells from the same BRCA1 mutant
specimen did not display higher intensity than their counterparts
in non-carriers (Fig. 1c,d). This luminal cell-specific R-loop
accumulation is reminiscent of the lineage-specific cell of origin
for BRCA1-associated breast tumours.
Genome-wide survey of R-loop accumulation. To corroborate
IF results and to identify the genomic locations of BRCA1
mutation-associated R-loop accumulation, we sorted breast cells
from fresh breast tissue and used them for R-loop-specific
DNA-RNA immunoprecipitation-sequencing (DRIP-seq)28.
Tissue samples from four BRCA1 mutation carriers (B1) and
four non-carriers (NC) were procured, digested into single cells
and sorted by flow cytometry using established cell surface
markers (EpCAM and CD49f; Fig. 2a and Supplementary
Fig. 2)29. Four distinct cell populations were acquired: stromal
cells, basal epithelial cells, luminal progenitor (LP) cells
and mature luminal epithelial (ML) cells. Each sorted cell
population was subjected to DRIP using an established protocol
and R-loop-specific antibody28. DNA samples from DRIP
reactions were amplified and used in deep sequencing. For
bioinformatics analysis, extracted reads were normalized to total
reads of a given sample (see Methods for details).
Using DRIP-seq data from the four BRCA1 mutation carriers
and four non-carriers, we found that R-loop levels in the two
luminal cell populations (LP and ML) were more pronounced
than basal epithelial and stromal cells from the same
cohorts (compare columns 1–4 with 5–8 in Fig. 2b), indicating
cell-type-specific R-loop accumulation regardless of the BRCA1
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Figure 1 | BRCA1 mutation-associated R-loop accumulates preferentially
in luminal breast epithelial cells. (a) Low and high (inlet) magnification
images of R-loop staining in samples from non-carriers and BRCA1 mutation
carriers, with and without pretreatment of RNase H. Scale bar, 20mm (left)
and 5 mm (right). (b) Quantitation of relative R-loop intensity in the
non-carrier group (NC; n¼ 36) and BRCA1 mutation carrier group (B1;
n¼ 55). ***Po0.001 by two-tailed t-test. (c) Image of R-loop staining
in BRCA1 mutation carriers. The dash line indicates the boundary between
luminal epithelial cells and stromal–basal cells. Scale bar, 5 mm.
(d) Quantitation of relative R-loop intensity in stromal–basal compartment
and luminal epithelial compartment in the non-carrier group (NC; n¼ 12),
BRCA1 mutation carrier group (B1; n¼ 12) and BRCA1 mutation carrier
pretreated with RNase H group (B1þRH; n¼ 5). **Po0.01 and
***Po0.001 by two-tailed t-test. Error bars represent s.e.m.
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mutant status. Furthermore, LP and ML populations of BRCA1
mutation carriers exhibited even higher R-loop levels than their
counterparts from non-carriers (compare column 5 with 6, and 7
with 8 in Fig. 2b). In contrast, overall R-loop intensity in stromal
and basal cell compartments was comparable between BRCA1
mutation carriers and non-carriers (compare column 1 with 2,
and 3 with 4). We confirmed the BRCA1 mutation-associated
R-loop enrichment by locus-specific PCR (Supplementary Fig. 3).
Furthermore, pretreatment with RNase H before DRIP
completely abolished the R-loop signals in locus-specific DRIP
and genome-wide DRIP-seq (Supplementary Fig. 4a,b), thus
corroborating the antibody specificity. Of note, a number of genes
involved in luminal fate determination and differentiation
showed luminal cell-specific enrichment of R-loop signals in
BRCA1 mutant samples, including XBP1, GATA3, CEBPB and
FOXC1 (multicolour overlay representing biological repeats in
Fig. 2c and Supplementary Figs 5 and 8). Interestingly, the R-loop
distribution at the XBP1 locus in vivo bears striking resemblance
to that of oestrogen-stimulated R-loops observed in a recent cell
culture study30. Taken together, DRIP-seq and IF using
independent cohorts of fresh and FFPE clinical samples,
respectively, lead us to the same conclusion that BRCA1
mutation carriers are associated with luminal cell-specific
R-loop accumulation in cancer-free breast tissue.
Genomic features of R-loop accumulation. Genome-wide
analyses indicate that overall R-loop intensity in both BRCA1
mutation carriers and non-carriers is most pronounced at the
50 end of genes, followed by the 30 end (Fig. 3a,b). As expected,
the gene body, gene distal and gene desert regions had relatively
low R-loop signals in both clinical cohorts. This finding is in line
with a recent report of prevalent and conserved R-loop formation
at promoter and terminator regions of Pol II-dependent genes in
human and mouse genomes31. Consistent with our prior data,
BRCA1 mutation-associated R-loop elevation was observed at
these genic hotspots only in cells of luminal lineage, but not in
stromal or basal epithelial cells (Fig. 3a). We define genes with
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Figure 2 | DRIP-seq validation of luminal lineage-specific R-loop accumulation in BRCA1 mutation carriers. (a) Experimental design for DRIP-seq. Fresh
cancer-free breast tissue samples were digested into single cells, and then sorted by flow cytometry into four populations: stromal, basal, LP and ML.
Genomic DNA from each population was extracted, digested and immunoprecipitated with an R-loop-specific antibody S9.6. DRIP DNA was subjected to
deep sequencing. (b) Average reads per 1Mb reads per 100 kb (from TSS to TTS) in stromal–basal–LP–ML population in non-carriers (n¼4) and BRCA1
mutation carriers (n¼4). **Pr0.01, ***Pr0.001 and ****Po0.0001 by permutation test. Error bars represent s.e.m. (c) Track view of DRIP-seq density
profile centred on gene XBP1. Each track is an overlay of four individual non-carriers (NC) or four BRCA1 mutation carriers (B1) indicated by different
colours. TSS was marked by red arrow.
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BRCA1 mutation-associated R-loop at TSS as those in either of
the following two groups: (1) TSS with R-loop peaks in both B1
and NC samples but average reads of B1 in TSS upstream/
downstream 2 kb region is greater than NC with log2 FCZ0.8,
adjusted P valuer0.05; (2) TSS with common R-loop peaks only
present in B1. Using a combined gene set consisting of both
groups of genes, we found that promoter regions with BRCA1
mutation-associated R-loops are enriched with binding sites for
breast cancer-related transcription factors, such as GATA3 and
FOXA1 in LP cells and SMAD2/4 and STAT6 in ML cells
(Fig. 3c). There are also significant overlaps between our gene list
and previously defined luminal signature genes (Supplementary
Data 1). Furthermore, gene ontology indicates that mammary
neoplasm is the top disease-associated category among genes with
BRCA1 mutation-associated R-loops (Supplementary Fig. 6).
R-loop accumulation is associated with Pol II pausing. Among
those genes with common promoter-associated R-loops in
BRCA1 mutation carriers, 88% do not share R-loops at the
corresponding terminator regions (Fig. 4a), suggesting that
distinct mechanisms are involved in the regulation of R-loop
dynamics at these two genic hotspots. In a recent genome-wide
study of R-loops in the K562 human erythroleukemia cell line31,
Chedin and co-workers31 showed that genes with
promoter-proximal R-loop formation display a significantly
higher level of nascent transcription immediately downstream
of TSS, coinciding precisely with the hotspot of R-loop formation.
This raised the distinct possibility that R-loop accumulation at
TSS could be associated with promoter-proximal Pol II pausing.
Using total Pol II chromatin immunoprecipitation-seq
(ChIP-seq) data from the same published study, we calculated
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Figure 3 | BRCA1 mutation-associated R-loop accumulates preferentially at transcription regulatory regions. (a) Box plot displaying average reads per
1Mb reads per 100 kb in the peak regions in stromal–basal–LP–ML in non-carriers (NC; n¼4) and BRCA1 mutation carriers (B1; n¼4). Peaks were
identified using uniquely mapped reads, and then extended to the closest restriction enzyme cutting site. Extended peaks from all samples were combined,
and categorized into TSS, gene body, TTS and distal peaks. For gene desert, reads fromB11,000 gene desert regions, each with the length of 20 kb were
used. Average reads per 1Mb reads per 100 kb were calculated in each category. ****Pr0.0001 permutation test. (b) Heatmap of averaged DRIP-seq
density in non-carriers (NC; n¼4) and BRCA1 mutation carriers (B1; n¼4) centred on TSS, gene body, TTS and distal regions. Ranked by BRCA1 mutation
carriers high to low. Heatmaps were drawn using genes that are top-ranked 5,000 in TSS region. Genes in each subpanel of heatmap are sorted individually.
(c) Cytoscape depicting HOMER motif analysis. Genes with BRCA1 mutation-associated R-loop at TSS in either LP or ML population were used as target
sequences for motif search. Background colour of motifs indicates the percentage of target sequences that has corresponding motif.
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Pol II pausing index based on previously established definition
(Supplementary Fig. 7a)32. In support, we found a strong positive
correlation between genes with promoter-proximal R-loop peaks
and Pol II-pausing index (P¼ 6.09 10 18 by signed rank-sum
test, Fig. 4b). A similar correlation was found between Pol II
pausing and high GC skew, a known predictor for
promoter-proximal R-loop accumulation28 (P¼ 2.32 10 15
by signed rank-sum test, Supplementary Fig. 7c). To
corroborate these cell culture-based findings, we conducted
total Pol II ChIP-seq using primary human breast epithelial
cells from fresh human breast tissue. Again, we observed a
remarkable concordance between genes with BRCA1 mutation-
associated R-loop and Pol II-pausing index at TSS in vivo
(P¼ 3.45 10 16 by signed rank-sum test, Fig. 4c). Taken
together, these correlative data are consistent with the notion that
promoter-proximal Pol II pausing and R-loop accumulation are
mechanistically linked.
COBRA1 depletion ameliorates BRCA1-associated R-loops.
The four-subunit NELF complex plays a key role in Pol II paus-
ing33. We previously reported a physical association between
BRCA1 and one of the NELF subunits, NELFB/COBRA1 (ref. 17).
In a more recent study, we provided compelling mouse genetic
evidence that BRCA1 and COBRA1 functionally antagonize each
other during normal mammary gland development22. We
therefore postulated that the same functional antagonism could
extend to the regulation of R-loop dynamics in such a manner that
NELF-mediated Pol II pausing leads to elevated R-loop signals in
BRCA1-deficient cells. Consistent with this notion, we found that
the expression of human COBRA1 positively correlates with R-loop
intensity in breast tissue of BRCA1 mutation carriers (P¼ 0.005,
Pearson’s correlation 0.37, Fig. 4d). Furthermore, using publicly
available ChIP-seq data for BRCA1 and NELF26,34,35, we observed a
significant overlap between BRCA1- and NELF-bound genes (P¼ 0
by Fisher’s test, Fig. 4e). An extensive overlap was also found
between BRCA1/NELF-bound genes and those with elevated TSS
R-loop signal in BRCA1 mutation carriers (P¼ 0 by Fisher’s test,
Fig. 4e).
To explore a functional link between promoter-proximal
NELF-mediated Pol II pausing and BRCA1-associated R-loop
accumulation, we knocked down (KD) BRCA1 and COBRA1 in
T47D luminal breast cancer cells (Fig. 5a). Locus-specific DRIP
showed that BRCA1 KD increased R-loop levels at two genic
regions that displayed elevated R-loop enrichment in vivo
(compare column 1 with 2 in Fig. 5b,c; Supplementary Fig. 8).
This effect of BRCA1 KD was verified by multiple independent
BRCA1-targeting short interfering RNA (siRNA) oligos
(Supplementary Fig. 9). Furthermore, the R-loop signals at both
loci were sensitive to RNase H pretreatment of genomic DNA
(columns 3–4 in Fig. 5b,c), thus confirming specificity of the
DRIP assay. As expected, depletion of COBRA1 significantly
c
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reduced Pol II-pausing index in both control and BRCA1 KD
cells (compare columns 1–2 with 3–4 in Fig. 5d,e), as calculated
based on the ratio of total Pol II ChIP signal at TSS over that at a
region in the gene body (Supplementary Fig. 7a,b). Of note,
BRCA1 KD alone did not affect Pol II pausing (compare column
1 with 2 in Fig. 5d,e). We interpret this to mean that BRCA1 acts
downstream of NELF-dependent Pol II pausing to alleviate
pausing-induced R-loop accumulation. Consistent with this
notion, ectopic expression of human RNase H1 in T47D cells
reduced R-loop intensity but not promoter-proximal Pol II
pausing (Supplementary Fig. 10). In further support of our
hypothesis, COBRA1 KD resulted in a significant reduction in
R-loop levels in BRCA1 KD cells (compare columns 2 with 4 in
Fig. 5f,g). Interestingly, COBRA1 KD did not lead to any
appreciable decrease in basal R-loop levels in control cells
(compare columns 1 with 3 in Fig. 5f,g). One explanation is that
the R-loop-attenuating activity of BRCA1 in control cells is
potent enough to prevent R-loop accumulation caused by
NELF-dependent Pol II pausing.
Cobra1 ablation mitigates mammary tumorigenesis.
To investigate the functional interaction between COBRA1 and
BRCA1-associated R-loop dynamics in vivo, we assessed R-loop
intensity in mammary gland-specific (MMTV-Cre) KO mice for
Brca1 (BKO), Cobra1 (CKO) and both genes (double knockout
(DKO))22. Consistent with our IF findings from human BRCA1
mutation carriers, the vast majority of luminal cells in BKO
mammary glands exhibited significantly higher R-loop staining
than their wild-type (WT) counterparts (Fig. 6a,b). The IF signal
was significantly diminished by pretreatment with RNase H
(þRH, Fig. 6a,b), confirming antibody specificity. Consistent
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with the findings of COBRA1 KD in cell culture, Cobra1 ablation
alone in mammary epithelium in vivo did not exhibit statistically
significant difference in R-loop intensity compared to their WT
counterparts (Fig. 6b). Remarkably, mammary epithelial cells of
Brca1/Cobra1 DKO displayed significantly reduced R-loop levels
versus those in BKO (Fig. 6a,b). This suggests that the R-loop
accumulation observed in Brca1-deleted mammary epithelium is,
to a large part, caused or reinforced by the action of COBRA1.
We then asked whether COBRA1 affects Brca1-associated
mouse mammary tumorigenesis. Consistent with published
findings36, BKO mice had increased spontaneous mammary
tumours (red, Fig. 6c). Hemizygous deletion of Cobra1 in the
BKO background (BKO, C-hemi) did not affect Brca1-associated
mammary tumorigenesis (green). In striking contrast, DKO mice
with homozygous deletion of Cobra1 and Brca1 (blue) exhibited
significantly lower mammary tumour incidence than BKO and
BKO, C-hemi mice (Fig. 6c). Despite the significant difference in
tumour incidence, tumours from DKO and BKO displayed
similar degrees of cell proliferation and apoptosis as measured by
Ki67 staining and TdT-mediated dUTP nick end labelling assay,
respectively (Supplementary Fig. 11). Thus, genetic ablation of
Cobra1 ameliorates Brca1-associated R-loop accumulation and
mammary tumour development, but it does not appear to affect
progression of Brca1-associated tumours once they are formed.
BRCA1 functions in HR repair9 and suppression of DNA
replication stress10–15 have been well documented. Furthermore,
a recent study shows that oestrogen-dependent R-loop formation
is associated with DNA replication-dependent double-strand
breaks30. Thus, Cobra1 ablation could reduce Brca1-associated
tumorigenesis by restoring HR repair and/or reducing elevated
DNA replication stress in Brca1-deficient mammary epithelial
cells. However, using both cell culture-based assay and mouse
genetic models, our published studies showed that mammary
epithelial cells of DKO mice exhibited the same degree of
HR repair deficiency as those in BKO22. Furthermore, DNA
replication stress as measured by 53BP1 staining among
5-bromodeoxyuridine-positive (BrdUþ ) cells was even more
pronounced in DKO versus BKO mammary epithelium (Fig. 6d).
Thus, reduced tumour incidence in DKO mice is unlikely due to
rescue of either HR repair defect or elevated DNA replication
stress associated with BRCA1 deficiency.
Discussion
Combined studies of clinical samples, cell culture and genetically
engineered mouse models lead us to the conclusion that
NELF-mediated Pol II pausing is an important source of R-loop
accumulation in BRCA1-deficient mammary epithelial cells.
Importantly, attenuation of Pol II pausing can mitigate R-loop
accumulation and reduce incidence of mammary tumour
development due to BRCA1 deficiency. It is conceivable that
nascent transcripts produced by promoter-proximally paused Pol
II are prone to R-loop formation. We propose that, through its
direct association with COBRA1 and perhaps other transcription
factors, BRCA1 is brought to genes with NELF-dependent Pol II
pausing to ameliorate promoter-proximal R-loop accumulation.
Reduced BRCA1 expression and/or activity, while not affecting
NELF-dependent Pol II pausing per se, can lead to excessive
elevation of R-loop signals at those gene loci. Although
NELF-dependent Pol II pausing is important for development-
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Figure 6 | Ablating COBRA1 mitigates BRCA1-associated R-loop accumulation and mammary tumorigenesis. (a) Low and high (inlet) magnification
images of R-loop staining in mammary ducts of 8-week-old virgin mice, with and without pretreatment of RNase H (RH). Scale bars, 5 mm (top) and 20mm
(bottom). (b) Quantitation of relative R-loop intensity in 8-week-old animals. The number of animals used in each group is: WT (n¼9), BKO (n¼ 9),
BKOþRH (n¼ 3), CKO (n¼ 5) and DKO (n¼8). *Po0.05 by two-tailed t-test. Error bars represent s.e.m. (c) Kaplan–Meier curve for tumour incidence.
**Po0.01 by log-rank test. (d) Percentage of BrdUþ mouse mammary epithelial cells with 53BP1 foci from 12-week-old mice. The number of animals used
in each group is: WT (3), BKO (3) and DKO (3). *Po0.05 by two-tailed t-test. Error bars represent s.e.m.
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related transcription22, the ensuing R-loop accumulation in the
absence of BRCA1 could ultimately contribute to tumorigenesis.
Thus, functional antagonism between BRCA1 and NELF enforces
a fine balance between normal tissue development and tumour
suppression.
Attenuated R-loop levels in DKO mice clearly correlates with
reduced tumour incidence. Consistent with previous reports, we
found that BRCA1-deficient mouse mammary epithelium is
associated with compromised HR repair22, elevated DNA
replication stress (Fig. 6d) and increased RANKL expression
(Supplementary Fig. 12a). However, unlike R-loop levels and
tumour incidence, none of these abnormalities in BKO mice was
rescued on further deletion of Cobra1 in DKO mice, nor were
there any significant changes in levels of oestrogen receptor or
progesterone receptor between BKO and DKO (Supplementary
Fig. 12b). Compared to their corresponding WT littermates,
neither BKO nor DKO exhibited substantial transcriptomics
changes in mammary epithelia (Supplementary Fig. 13 and
Supplementary Data 2). Future studies will shed light on the
underlying mechanism by which BRCA1/COBRA1-regulated
R-loop dynamics influences BRCA1-associated tumour
development.
DRIP-seq of clinical samples from both BRCA1 mutation
carriers and non-carriers identifies significantly elevated overall
R-loop levels in luminal cells compared to basal and stromal cells.
A recent epigenomic and transcriptomic study of human
breast showed that luminal cells have twice the number of
hypomethylated transcription enhancers and approximately four
times the amount of total RNA compared with myoepithelial
cells37. This remarkable asymmetry of epigenetics status and
steady-state transcript abundance is consistent with the notion
that the higher R-loop levels in luminal cells result from more
active nascent transcription. However, direct measurement of
nascent transcripts in human breast is technically challenging,
because of the extensive tissue processing in vitro and limited
number of resulting sorted primary cells. A related question
concerns the luminal-specific R-loop accumulation in BRCA1
mutation carriers. Because no R-loop elevation was observed at
transcriptionally active genes in either stromal or basal cells of the
same BRCA1 mutation-carrying individuals, the BRCA1
mutation-associated R-loop elevation in luminal cells is unlikely
to be a mere by-product of active transcription per se. BRCA1 is
functionally and/or physically associated with a number of
luminal cell-specific transcription factors that are involved in fate
determination, including ERa, GATA3 and FOXA1
(refs 7,16,38,39). These functional links could in turn confine
BRCA1 action to transcriptional regulatory regions in the luminal
cell compartment.
MMTV-Cre-based gene KO tends to be biased towards the
luminal compartment of mouse mammary epithelium.
Nevertheless, BRCA1 expression in BKO mice used in the
current study was reduced equally effectively in luminal and basal
epithelial compartments (Supplementary Fig. 14). Thus, data
from both mouse models and human clinical samples are valid in
demonstrating cell lineage-specific R-loop enrichment. However,
we realize that Brca1 KO mouse models do not entirely
recapitulate disease development in human BRCA1 mutation
carriers. For example, unlike humans, tumour incidence is not
higher in heterozygous Brca1 KO mice versus WT mice40.
Despite these species-dependent differences, parallel investigation
of both clinical samples and mouse genetic models promises to
shed more light on a clinically relevant and biologically
underinvestigated problem.
Genetic complementation between mouse Brca1 and Cobra1 in
R-loop dynamics and mammary tumorigenesis strongly suggests
that COBRA1 contributes to BRCA1-associated breast cancer
development. This is further supported by the positive correlation
between COBRA1 expression and R-loop intensity in breast
epithelium of BRCA1 mutation carriers. It is also worth noting
that tumour samples from triple-negative breast cancer patients,
which contain the majority of BRCA1 mutation carriers, had
significantly elevated COBRA1 mRNA as compared to normal
breast epithelium from cancer-free individuals41 (2.55-fold,
P¼ 4.83 10 6 by two-tailed t-test). In summary, our study
suggests that NELF-dependent Pol II pausing is a previously
unappreciated contributor to tumour development in
BRCA1-deficient breast epithelium, which offers a potential
cancer risk-assessing and -reducing tool.
Methods
Mice. Cobra1f/f mice have been described previously42. Brca1f/f mice36 were
obtained from Mouse Model of Human Cancer Consortium, National Cancer
Institute.MMTV-Cre line A mice (from Dr Anthony Wynshaw-Boris) were used to
generate MMTV-Cre,Brca1f/f, MMTV-Cre,Cobra1f/f and MMTV-Cre,Brca1f/f,
Cobra1f/f as described previously22. Mutant mice and their littermate controls in
the same mixed genetic background (129SvEv/SvJae/C57BL6/FVB) were analysed.
All procedures performed on animals were approved by the Institutional Animal
Care and Use Committee at the University of Texas Health Science Center at San
Antonio.
Breast tissue cohorts. Cancer-free breast tissue was procured from women
either undergoing cosmetic reduction mammoplasty, diagnostic biopsies or
mastectomy, following protocols approved by the Institutional Review Board at the
Georgetown University, the Catalan Institute of Oncology, PRMA Plastic Surgery
and the University of Texas Health Science Center at San Antonio. All donors
signed written consent forms authorizing the use of the specimens for breast
cancer-related laboratory investigations.
Cell culture. T47D was purchased from ATCC and cultured in high glucose
DMEM (Thermo Fisher Scientific; 11965) supplemented with 10% foetal bovine
serum (FBS), 100 mgml 1 penicillin and 100 mgml 1 streptomycin (Thermo
Fisher Scientific; 15140122). siRNA pools for non-targeting control (Dharmacon;
D-001810-10) was purchased. Individual siRNAs were synthesized from
Sigma-Aldrich. siRNA target sequences are listed in Supplementary Table 1. siRNA
transfection was carried out using Lipofectamine RNAiMAX (Thermo Fisher
Scientific; 13778150) following the manufacturer’s instruction. Briefly, 20 nM of
siRNA was transfected with 25 ml of RNAiMAX reagent. Cells were collected 3 days
after siRNA transfection.
Human RNASEH1 gene (Addgene; 65782) was subcloned into pCDH-EF1-
MCS-T2A-Puro lentivector (System Biosciences; CD520A-1) via EcoRI/BamHI
restriction sites. Control and RNase H1 lentiviruses were produced in HEK293T
cells by co-transfecting cells with the lentiviral vectors and the corresponding
helper plasmids using Lipofectamine 2000 (Thermo Fisher; 11668019). Viral
supernatant was collected 48 h after transfection, and was passed through a
0.45 mM filter before titration. Lentiviruses were titred using a Quantitative
PCR-Based Lentivirus Titration Kit (Applied Biological Materials; LV900)
following the manufacturer’s instruction. Control and RNase H1 lentiviruses of the
same titre were used to infect T47D cells with 0.8 ml ml 1 polybrene (Millipore;
TR-1003-G). T47D cells were collected 72 h after infection and proceeded to DRIP
and ChIP assays. Immunoblotting was performed to confirm RNase H1
overexpression (Proteintech; 15606-1-AP). PCR with reverse transcription for
mRNA abundance was carried out using the primers listed in Supplementary
Table 2.
Protein IF/immunohistochemistry staining. Twelve-week-old virgin mice were
intraperitoneally injected with cell proliferation labelling reagent (GE Healthcare;
RPN201) at 16.7ml kg 1. After 3 h, their inguinal mammary glands were removed
and fixed with 10% neutral-buffered formalin (Fisher Scientific; 23245685) at 4 C
overnight. Fixed glands were paraffin embedded and cut into 3 mM sections for
staining. Slides were baked at 70 C for 15min, and then deparaffinized/rehydrated
by 100% xylene, 100% xylene, 100% xylene, 100% ethanol, 100% ethanol, 95%
ethanol, 70% ethanol, 50% ethanol for 3min each. After briefly washing with PBS,
slides were boiled with antigen-unmasking solution (Vector Labs; H-3300) for
20min. Slides were cooled down to room temperature, washed with PBS and
blocked with 10% normal goat serum in PBS at room temperature for 1 h. Primary
antibody incubation was done at 4 C overnight. Primary antibodies used were:
anti-BrdU (GE Healthcare; RPN20; 1:10,000), anti-53BP1 (Bethyl Laboratories;
A300-272A; 1:500). After primary antibody incubation, slides were washed
with PBS and incubated with Alexa-488- and Alexa-546-conjugated secondary
antibodies (Life Technologies) at room temperature for 2 h. Slides were washed and
mounted with Vectashield mounting medium with 40 ,6-diamidino-2-phenylindole
(DAPI) (Vector Labs; H-1200). A DeadEnd Fluorometric TUNEL System Kit
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(Promega; G3250) was used for in situ nick-end labelling of DNA fragmentation
according to the manufacturer’s instructions.
For immunohistochemistry staining, slides were deparaffinized/rehydrated,
boiled with antigen-unmasking solution, cooled down and washed as mentioned
above. Slides were pretreated with 3% hydrogen peroxide for 10min before
blocking. Primary antibodies used were: anti-COBRA1 as described previously24,
anti-Ki67 (Thermo Fisher Scientific; MA5-14520; 1:100) and anti-RANKL (R&D
Systems; AF462; 1:300). For detection of primary antibody using immune
enzymatic method, the ABC Peroxidase Detection System (Vector Labs; PK-6105)
was used with 3, 30-diaminobenzidine (DAB) as substrate (Vector Labs; SK-4105)
according to the manufacturer’s instruction.
R-loop IF staining. Freshly cut 3 mM FFPE samples were baked at 70 C for
15min. After deparaffin and rehydration, samples were treated with boiling
antigen-unmasking solution for 1 h. Samples were cooled down to room
temperature, and then treated with 0.2 SSC buffer (Ambion; AM9763) with
gentle shaking at room temperature for 20min. Primary antibody incubation was
done with monoclonal antibody S9.6 (Karafast; ENH001) at 1:100 dilution in PBS
containing 1% normal goat serum and 0.5% Tween-20 at 37 C overnight. After
primary antibody incubation, samples were washed three times with PBS con-
taining 0.5% Tween-20, and then incubated with Alexa-488-conjugated secondary
antibody at 1:1,000 dilution in PBS containing 1% normal goat serum and 0.5%
Tween-20 at 37 C for 2 h. Samples were washed two times with PBS containing
0.5% Tween-20, two times with PBS, and then mounted with Vectashield mounting
medium with DAPI. For samples pretreated with RNase H, an overnight treatment
of RNase H (NEB; M0297S) was carried out after 0.2 SSC treatment. Samples
were washed three times with PBS before primary antibody incubation.
Quantification of immunostaining. R-loop intensity was quantified using the
MetaMorph Microscopy Automation and Image Analysis Software 7.8. For each
image, the DAPI signal was used to create a mask of the nucleus in either luminal
epithelial compartment or basal/stromal compartments. R-loop intensity was
determined by calculating the average intensity in the mask. COBRA1
immunohistochemistry staining images were first separated into haematoxylin and
DAB channels using Colour Deconvolution plugin in ImageJ. Intensity of COBRA1
nuclei staining was analysed using the regions of interest (ROIs) and ROI statistics
features in Nikon NIS-Elements BR Analysis package. The haematoxylin channel
was used to create ROIs in the nucleus of epithelial compartment. The selected
ROIs were then pasted to the corresponding DAB channel to determine the mean
intensity of COBRA1. At least four images, each of which contained a minimum of
one complete epithelial duct, were acquired for each sample. The fields were
selected by investigators who were blind to sample genotype. The final intensity for
each sample is the average of all images. Quantification of Ki67þ and TUNELþ
cells was done by ImageJ particle analysis software.
Single-cell isolation of human breast tissue. Fresh unfixed human breast tissue
procured from either cosmetic reduction mammoplasty or mastectomy was
processed following the previously published procedure with minor modification43.
All reagents were purchased from StemCell Technologies (Vancouver, BC,
Canada), unless otherwise indicated. Briefly, tissue was minced with scalpels and
digested for 15–18 h at 37 C with shaking in DMEM/F-12 supplemented with 5%
FBS, 300Uml 1 collagenase and 100Uml 1 hyaluronidase, 0.1% BSA (Fisher
Scientific; BP1600-100), 10 ngml 1 epidermal growth factor (Invitrogen;
PHG0311L), 10 ngml 1 cholera toxin (Sigma; C8052), 5 mgml 1 insulin (Sigma;
I0526) and 0.5mgml 1 hydrocortisone (Sigma; H0888). An epithelial-rich
organoid was obtained by centrifugation at 100g for 3min. Red blood cells in the
resulting pellets were lysed with 0.8% NH4Cl. Organoids were digested with 0.05%
trypsin-EDTA (Life Technologies; 25300), washed with Hank’s balanced salt
solution supplemented with 2% FBS and then resuspended in 5mgml 1 Dispase
(cat. no. 07913) containing 0.1mgml 1 DNase I (Roche; 10104159001). Single
cells were obtained by going through a 40-mm filter (Fisher; 22363547) to remove
remaining cell aggregates.
Flow cytometry and cell sorting. Single cells isolated from digested breast tissue
were counted and resuspended in Hank’s balanced salt solution supplemented
with 2% FBS at a concentration of 1 106 cells per 100ml. Cells were preblocked
with 10% rat serum on ice for 10min, and then stained with a rat anti-CD49f
allophycocyanin-conjugated antibody (R&D Systems; clone GOH3) and mouse
anti-EpCAM FITC-conjugated antibody (StemCell Technologies; clone VU1-D9)
following a previously published protocol43. Mouse anti-CD45 (eBiosciences; clone
H130), anti-CD235a (eBiosciences; clone HIR2) and anti-CD31 (eBiosciences;
clone WM59) biotin-conjugated antibodies were used to label haematopoietic and
endothelial cells, followed by Pacific Blue-conjugated Streptavidin (Thermo Fisher
Scientific; S11222) incubation. Cells were incubated with 7-aminoactinomycin D
(BD Biosciences; 559925) before analysis to distinguish live and dead cells. Cell
sorting was performed with a BD FACSAria Flow Cytometer (BD Biosciences).
Cells were separated into the following four fractions: EpCAMCD49f stromal
cells, EpCAMlowCD49fhigh basal epithelial cells, EpCAMhigh CD49fþ luminal
progenitor cells and EpCAMhigh CD49f mature luminal epithelial cells. Purity of
the stromal, basal, luminal progenitor and mature luminal populations were
verified by real-time PCR analysis of VIM (stromal), KRT14 (basal), KRT18
(luminal) and ESR1 (mature luminal) mRNA using ACTB for normalization.
ChIP assay. Cells were crosslinked with 1% formaldehyde at room temperature for
10min, and the reaction was terminated with 125mM glycine at room temperature
for 5min. The crosslinking reagent was removed by spinning at 1,000g at 4 C for
5min, and then cells were washed with cold PBS three times. From this step on to
ChIP elution, all buffers were prepared with freshly added cocktail of phosphatase
and protease inhibitors (10mM sodium fluoride, 10mM sodium pyrophosphate
tetrabasic, 2mM sodium orthovanadate, 1 mgml 1 leupeptin, 1 mgml 1 aprotinin,
1 mgml 1 pepstatin and 1mM phenylmethylsulfonyl fluoride). Cells were lysed on
ice for 10min using lysis buffer (5mM HEPES, pH 7.9, 85mM KCl, 0.5% Triton
X-100). Supernatant was removed after spinning at 1,600g at 4 C for 5min, and
pellet was resuspended with nuclei lysis buffer (50mM Tris-HCl, pH 8.0, 10mM
EDTA, 1% (wt vol 1) SDS). Chromosomal DNA was sonicated using a probe
sonicator on ice, then centrifuged at 14,000g for 15min and the supernatant was
saved. Ten per cent of the sonicated DNA was saved as input, the rest was
used for ChIP. Antibodies used for ChIP include: anti-Pol II (Abcam; ab817) and
anti-NELF-A, which was described previously44. Sonicated DNA was incubated
with antibody at 4 C overnight. Dynabeads Protein A (Thermo Fisher Scientific;
10002D) was added the following day and incubated for 4 h. After incubation,
Dynabeads was washed two times in TE sarcosyl buffer (50mM Tris-HCl, pH 8.0,
2mM EDTA, 0.2% sarcosyl), two times in TSE1 buffer (150mM sodium chloride,
20mM Tris-HCl (pH 8.0), 2mM EDTA, 0.1% (wt vol 1) SDS, 1% Triton-X-100),
two times in TSE2 buffer (500mM sodium chloride, 20mM Tris-HCl, pH 8.0,
2mM EDTA, 0.1% (wt vol 1) SDS, 0.1% Triton X-100), two times in TSE3 buffer
(250mM lithium chloride, 10mM Tris-HCl, pH 8.0, 1mM EDTA, 1% sodium
deoxycholate, 1% NP-40) and two times in TE buffer (50mM Tris-HCl, pH 8.0,
2mM EDTA). Samples were subsequently eluted and reverse-crosslinked and
ethanol-precipitated. Locus-specific ChIP signals were assessed by PCR using
primers as shown in Supplementary Table 3.
DNA-RNA immunoprecipitation. DRIP assay was performed following the
established protocol28. Briefly, cells were washed two times in PBS and resuspended
in TE (Sigma; T9285) containing 5 ml of proteinase K (Roche; 03115828001) and a
final concentration of 0.5% SDS. Samples were incubated overnight at 37 C.
Genomic DNA was extracted using phenol–chloroform (Sigma; P2069) in phase
lock tubes (5PRIME; 2302840) and ethanol precipitated. DNA was digested using
established restriction enzyme cocktail (HindIII, EcoRI, BsrGI, XbaI and SspI)
overnight at 37 C. Digested DNA was cleaned up by phenol–chloroform
extraction and ethanol precipitation. For DRIP, digested DNA was incubated with
S9.6 antibody overnight at 4 C in binding buffer (10mM sodium phosphate,
140mM sodium chloride, 0.05% Triton X-100 in TE). As a negative control for
DRIP, digested DNA was treated overnight with RNase H (NEB; M0297S) and
then precipitated for DRIP. Dynabeads were added the next day for 2 h. Bound
Dynabeads were then washed with binding buffer three times at room temperature.
DNA was eluted, phenol–chloroform extracted and ethanol precipitated. DRIP
DNA was sonicated using Covaris (Model S220) before library preparation. Locus-
specific DRIP signals were assessed by PCR using primers listed in Supplementary
Table 4.
Library preparation and sequencing. DRIP-seq libraries were built following
the instruction of MicroPlex Library Preparation Kit (Diagenode; C05010011).
A total of 15 cycles of PCR amplification was performed. After amplification,
libraries were purified using Agencourt AMPure XP System (Beckman Coulter;
A63880) following the product manual. Quantity of the libraries was measured
with Qubit dsDNA HS Assay Kit (Life Technologies; Q32851), and quality of the
libraries was verified using Bioanalyser 2100. Libraries were pooled based on index
sequences. Library pool of 14 pM was loaded to Illumina HiSeq2000 and sequenced
by 50 bp single-read sequencing module. After sequencing run, demultiplexing
with CASAVA was employed to generate the FASTQ file for each sample. Four
biological replicates were used for DRIP-seq and between 38 and 114 million total
reads were obtained for each biological sample.
Bioinformatics analysis of DRIP-seq. Reads in FASTQ file were aligned to
human genome by BWA45, a software package for mapping low-divergent
sequences against reference genome, and only unique mapped reads were selected
for analysis. We used Perl script to extract the unique mapped reads in four
regions, namely TSS region (up- and downstream 2 kb of transcription starting
site), TTS region (up- and downstream 2 kb of transcription terminating site), gene
body region (downstream 2 kb of TSS to upstream 2 kb of TTS), distal region
(upstream 100 to 2 kb of TSS) and gene desert region (1mb away from any TSS).
For each of 31,823 annotated genes with unique TSS and TTS, extracted reads were
normalized to total reads of each sample, and averaged for B1 and NC before being
applied with a signed t-test for differential R-loop in B1 samples. For gene body
region that iso2 kb in length, a signed rank-sum test was used instead. A log 2FC
cutoff 0.8 and adjusted P value 0.05 were used to define differential R-loop for any
given gene. P value in Figs 2b and 3a was calculated using permutation test by
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randomly regrouping values in NC and B1, to test the significance that average
R-loop in B1 is higher than that in NC. MATLAB for Linux was used to carry out
the permutation test. Heatmap of reads was generated using MATLAB to show the
reads in TSS, TTS, gene body and distal region for genes that are top ranked 5,000
in TSS region. Genes in each subpanel of heatmap are sorted individually.
Peak-calling program MACS (version 1.4, q value¼ 0.01) was used to identify
the peaks (R-loop binding sites) from uniquely mapped reads46. Peak loci were first
extended to nearest enzyme (HindIII, EcoRI, BsrGI, XbaI and SspI), and then TSS-
bound peaks were identified by 1 bp overlap to 50 TSS of human reference genes.
For each group of samples (B1 or NC), we selected genes that were associated with
TSS-bound peaks in all four samples of that group. Venn diagrams of the overlap
genes were generated by BioVenn47, a web application for comparison and
visualization of biological lists. The P value of the significance of the overlap in the
Venn diagrams was calculated by Fisher’s test.
Pausing index (or travelling ratio) is defined previously32, which is the ratio of
total Pol II density in the promoter-proximal region to the total Pol II density in
the transcribed region. Promoter-proximal region is defined as TSS upstream 30 bp
to downstream 300 bp, and transcribed region is from TSS downstream 300 bp to
TTS. Curves in Fig. 4b,c and Supplementary Fig. 7c are the accumulative
distribution of the percentage of Pol II-bound genes with a given pausing index.
P values were calculated using signed rank-sum test between the values of NC and
B1 at each data point.
HOMER program with default parameter was used for prediction of
transcription factor binding sites among TSS regions of genes with BRCA1
mutation-associated R-loop48. The TSS regions chosen as the background include
those containing R-loop peaks in both B1 and NC samples and the difference in
TSS R-loop intensity hold a P value 40.05.
GC skew28 was predicted by SkewR, which uses StochHMM, a Hidden Markov
Model software, to predict R-loop-binding regions. The program clusters genes
into four skew classes as Strong, Weak, No and Reverse Skew. SkewR was trained
on hg19 human genome using default parameters. We only used Strong and Weak
Skew genes as genes with GC skew.
Statistics for mouse tumour study/patient sample analysis. For the clinical
sample analysis, treatment groups (carrier, control) were contrasted. For the animal
tumour study, time-to-event data were summarized by treatment group with
Kaplan–Meier curves and groups were contrasted with regard to time event with
log-rank tests. All statistical testing was two sided with a significance level of 5%.
SAS Version 9.4 for Windows (SAS Institute, Cary, NC, USA) was used
throughout.
Data availability. Sequence data that support the findings of this study have been
deposited in NIH Gene Expression Omnibus (GEO) with the accession codes
GSE96672. All other remaining data are available within the article and
Supplementary Files, or available from the authors on request.
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